scholarly journals An Unusual Case of High Grade Triple Negative Intracystic Solid Papillary Carcinoma of Breast with Invasive Component

2017 ◽  
Vol 07 (02) ◽  
Author(s):  
Junainah E ◽  
Baslaim M ◽  
Shigairi S ◽  
Nemenqani D ◽  
Saber A ◽  
...  
Keyword(s):  
Papillary Carcinoma ◽  
Unusual Case ◽  
Triple Negative ◽  
High Grade ◽  
Solid Papillary Carcinoma ◽  
Invasive Component

Artefactual Epithelial Displacement in a Papilloma with Extensive Usual Duct Hyperplasia Mimics a Solid Papillary Carcinoma with Invasive Growth

2021 ◽  
pp. 106689692199158
Author(s):  
Aline François ◽  
Christine Galant ◽  
Martine Berlière ◽  
Mieke R. Van Bockstal
Keyword(s):  
Papillary Carcinoma ◽  
Invasive Carcinoma ◽  
Myoepithelial Cells ◽  
High Grade ◽  
Biopsy Needle ◽  
Nuclear Atypia ◽  
Solid Papillary Carcinoma ◽  
Needle Tract ◽  
Cytokeratin 5 ◽  
Immunohistochemical Profile

Mammary solid papillary carcinoma and usual duct hyperplasia (UDH) of the breast are morphological look-alikes, characterized by cellular streaming, solid growth, and a lack of high-grade nuclear atypia. Here, we report a challenging papillary lesion in the breast of a 48-year-old woman that presented with a double pitfall. A core needle biopsy showed a solid papillary proliferation of epithelial cells with oval to round overlapping nuclei, surrounded by a sclerotic stroma. This distorted lesion contained peripheral clefts and cellular streaming, without high-grade nuclear atypia. Immunohistochemistry showed diffuse heterogenous immunoreactivity for estrogen receptor and cytokeratin 5, and no immunoreactivity for chromogranin and synaptophysin. The immunohistochemical profile distinguished this sclerosed papilloma with extensive UDH from a solid papillary carcinoma. The lumpectomy specimen revealed a second challenge, where multiple epithelial islets without surrounding myoepithelial cells were observed near the papilloma, mimicking an invasive carcinoma. These islets displayed the same immunohistochemical profile as the sclerosed papilloma and they were surrounded by steatonecrosis and reactive fibroblasts, indicating epithelial displacement within the biopsy needle tract. A sclerosed papilloma with extensive UDH is a morphologically challenging mimic of a solid papillary carcinoma. Immunohistochemistry is helpful to distinguish both entities from one another. Extensive epithelial displacement in the biopsy tract made this case particularly challenging, as the displaced epithelial islets mimicked an invasive carcinoma. Pathologists should be aware of this uncommon double pitfall to prevent misdiagnosis.

An unusual case of intracystic papillary carcinoma of breast with invasive component

2014 ◽  
Vol 3 (3) ◽  
pp. 762
Author(s):  
Kishor H Suryawanshi ◽  
Dhiraj B Nikumbh ◽  
Rajshri P Damle ◽  
NV Dravid ◽  
Yogesh Tayde
Keyword(s):  
Papillary Carcinoma ◽  
Unusual Case ◽  
Invasive Component ◽  
Intracystic Papillary Carcinoma

scholarly journals An Unusual Case of Invasive Encapsulated Papillary Carcinoma of the Breast: A Case Report

2020 ◽  
Vol 33 (12) ◽  
pp. 838
Author(s):  
Xavier De Sousa ◽  
Pedro Santos Ferreira ◽  
Isabel Lopes Martins ◽  
Manuel Vitor Rigueira
Keyword(s):  
Papillary Carcinoma ◽  
Unusual Case ◽  
Triple Negative ◽  
Axillary Lymph Nodes ◽  
Clinical Approach ◽  
Low Grade ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Carcinoma Of The Breast ◽  
Rare Type

Papillary carcinoma of the breast is a rare type of breast malignancy, making up less than 2% of breast cancers, and only some are encapsulated papillary carcinoma. Usually, EPC are low-grade luminal like tumors. The authors report a case of a 50-year-old female with the diagnosis of an unusual high-grade triple negative encapsulated papillary carcinoma with an area of invasive papillary carcinoma and negative axillary lymph nodes. Considering its rarity, the description of this case and its clinical management are important in order to better understand this entity and choose the best clinical approach.

scholarly journals Invasive solid papillary carcinoma with neuroendocrine differentiation of the breast: a case report and literature review

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Xue Lin ◽  
Yoshiaki Matsumoto ◽  
Tomomi Nakakimura ◽  
Kazuo Ono ◽  
Shigeaki Umeoka ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Papillary Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Solid Papillary Carcinoma

Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. TPS5600-TPS5600
Author(s):  
Ramaswamy Govindan ◽  
Amanda Rose Townsend ◽  
Kathy D. Miller ◽  
Inderjit Mehmi ◽  
Yasutoshi Kuboki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Plasma Concentration ◽  
Adverse Events ◽  
Solid Tumors ◽  
Triple Negative ◽  
Phase 1 ◽  
Locally Advanced ◽  
Maximum Plasma ◽  
High Grade ◽  
Serous Ovarian Cancer

TPS5600 Background: KIF18A is a mitotic kinesin motor protein that regulates chromosome positioning during cell division and is overexpressed in a subset of human cancers. TP53 mutant unstable aneuploid cancer cells with chromosomal instability (CIN) features are dependent on KIF18A motor activity to prevent lethal multipolar cell division. Preclinical data demonstrate that treatment with AMG 650; an oral, first in class, selective small molecule inhibitor of KIF18A may be safe and tolerable. We are conducting a first-in-human phase 1 study with AMG 650 in adult subjects with locally advanced or metastatic solid tumors with TP53MUT, triple negative breast cancer (TNBC), high grade serous ovarian cancer (HGSOC) or serous like endometrial cancers and other solid tumors. Methods: In this phase 1, multicentric, dose escalation and dose expansion study we evaluate the safety and tolerability of AMG 650 monotherapy in patients with advanced/metastatic solid tumors (NCT04293094). The main objective is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) based on emerging safety, efficacy, and pharmacodynamics (PD) data prior to reaching the MTD. Key inclusion criteria include the presence of measurable disease and diagnosis of advanced/metastatic triple negative breast cancer (TNBC), high-grade serous ovarian cancer (HGSOC), serous-like endometrial cancer or other solid tumors with documented TP53 mutations. In the dose expansion phase, participants with locally advanced or metastatic TNBC or HGSOC will be treated with the preliminary RP2D identified from the dose exploration part of the study. Primary endpoints include the incidence of Dose Limiting Toxicities (DLTs),Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Treatment-related Adverse Events and the evaluation of the number of participants who experience a clinically significant change from baseline in vital signs, electrocardiogram and laboratory tests parameters. Secondary endpoints include Objective Response Rate, Duration of Response, Progression-free Survival, Clinical Benefit Rate, Time to Response, Time to Progression, Overall Survival (OS), Maximum Plasma Concentration (Cmax) of AMG 650, Time to Maximum Plasma Concentration (Tmax) of AMG 650 as well as Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval for AMG 650. Continuous monitoring of toxicity is conducted. The study began enrolling pts in March 2020 and is ongoing. For more information, please contact Amgen Medical Information: [email protected] Clinical trial information: NCT04293094.

scholarly journals Use of immunohistochemical analysis of CK5/6, CK14, and CK34betaE12 in the differential diagnosis of solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia of the breast

2018 ◽  
Vol 6 ◽  
pp. 205031211881154 ◽  
Author(s):  
Ichiro Maeda ◽  
Shinya Tajima ◽  
Yoshihide Kanemaki ◽  
Koichiro Tsugawa ◽  
Masayuki Takagi
Keyword(s):  
Differential Diagnosis ◽  
Papillary Carcinoma ◽  
Carcinoma In Situ ◽  
Immunohistochemical Staining ◽  
Immunohistochemical Analysis ◽  
Intraductal Papilloma ◽  
Solid Papillary Carcinoma ◽  
Usual Ductal Hyperplasia ◽  
Ductal Hyperplasia

Objectives: The aim of this study was to use immunohistochemistry to differentiate solid papillary carcinoma in situ from intraductal papilloma with usual ductal hyperplasia (IPUDH). Three types of high-molecular-weight cytokeratins (CKs) – CK5/6, CK14, and CK34betaE12 – were targeted. Methods: We studied 17 patients with solid papillary carcinoma in situ and 18 patients with IPUDH diagnosed by at least two pathologists. Immunohistochemical analyses used antibodies to CK5/6, CK14, and CK34betaE12 to make the differential diagnosis of solid papillary carcinoma in situ versus IPUDH. Immunohistochemical staining was scored as 0–5 using Allred score. Results: Immunohistochemistry with CK5/6 and CK14 antibodies produced scores of 0–3 in all patients with solid papillary carcinoma in situ and 2–5 in all patients with IPUDH. Immunohistochemical staining with CK34betaE12 antibody produced scores of 1–3 in all patients with solid papillary carcinoma and 3–5 in all patients with IPUDH. In tissues from patients with IPUDH, significantly more cells were stained with CK34betaE12 than CK5/6 ( p < 0.05) or CK14 ( p < 0.05). Conclusion: The immunoreactivity of CK5/6, CK14, and CK34betaE12 antibodies was useful to differentiate solid papillary carcinoma in situ from IPUDH. CK34betaE12 is especially useful for distinguishing solid papillary carcinoma from IPUDH.

scholarly journals Simultaneous Papillary Carcinoma in Thyroglossal Duct Cyst and Thyroid

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Gustavo Cancela e Penna ◽  
Henrique Gomes Mendes ◽  
Adele O. Kraft ◽  
Cynthia Koeppel Berenstein ◽  
Bernardo Fonseca ◽  
...  
Keyword(s):  
Papillary Carcinoma ◽  
Unusual Case ◽  
Incidental Finding ◽  
Thyroglossal Duct Cyst ◽  
Papillary Thyroid ◽  
Management Options ◽  
Current Management ◽  
Duct Cyst ◽  
Thyroglossal Duct ◽  
Sistrunk Procedure

Thyroglossal duct cyst (TDC) is a cystic expansion of a remnant of the thyroglossal duct tract. Carcinomas in the TDC are extremely rare and are usually an incidental finding after the Sistrunk procedure. In this report, an unusual case of a 36-year-old woman with concurrent papillary thyroid carcinoma arising in the TDC and on the thyroid gland is presented, followed by a discussion of the controversies surrounding the possible origins of a papillary carcinoma in the TDC, as well as the current management options.

scholarly journals Solid papillary carcinoma of the breast

2022 ◽  
Vol 12 ◽  
pp. e2021352
Author(s):  
Toyaja Jadhav ◽  
Shashi Shekhar Prasad ◽  
Bhupesh Guleria ◽  
Manvir Singh Tevatia ◽  
Prerna Guleria
Keyword(s):  
Papillary Carcinoma ◽  
Carcinoma Of The Breast ◽  
Solid Papillary Carcinoma

scholarly journals A STUDY ON THE HISTONE METHYLTRANSFERASE ENHANCER OF ZESTE HOMOLOG 2 EXPRESSION IN BREAST CARCINOMA

2020 ◽  
pp. 66-68
Author(s):  
Rubaiya Ahmad ◽  
Syed Meraj Imam ◽  
Debarshi Jana
Keyword(s):  
Breast Carcinoma ◽  
Breast Tumor ◽  
Triple Negative ◽  
Histone Methyltransferase ◽  
Expression Level ◽  
High Grade ◽  
Over Expression ◽  
Ezh2 Expression ◽  
Triple Negative Breast Carcinoma ◽  
Enhancer Of Zeste

The over expression of EZH2 in Breast Carcinoma. Compare EZH2 expression in different immunophenotypes of breast carcinoma(basal, luminal, triple-negative). The study EZH2 expression level in association to staging and grading of breast carcinoma Patients attending the Dept of Pathology, Sri Krishna Medical Collage Muzaffarpur, Bihar with epithelial breast tumor. We found that EZH2 in Breast Carcinoma was significantly associated with grade of the tumour. EZH2 was significantly associated with stage of the tumour. It was found that EZH2 was significantly correlated with ki67 in Breast Carcinoma patients. Triple negative Breast Carcinoma patient was significantly associated with high grade of EZH2 tumour.

Sign in / Sign up

Export Citation Format

Share Document